FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2583508733> ?p ?o ?g. }

• W2583508733 abstract "Abstract Abstract 5015 Lyn is a member of the Src kinase (SFK) family and controls the activation threshold of multiple signaling pathways in different types of cells, including B cells (Yamanashi et al., 1989, PNAS). Multiple myeloma (MM) is a hematological malignancy of plasma cells. In MM, Lyn is involved in IL-6-induced cell proliferation (Hallek et al., 1997, Exp Hematol). As one of the most important growth and anti-apoptotic factors for MM cells, both the IL-6/STAT3 and IL-6/ERK pathways have been shown to promote MM cell proliferation and prevent apoptosis. However, STAT3 and ERK activation is not sufficient for IL-6-induced proliferation, which further requires the activation of SFK (Ishikawa et al., 2002, Blood). IL-6-induced proliferation of U266 myeloma cells has been reported to be significantly suppressed following exposure to Lyn-specific antisense oligonucleotides or a Src kinase inhibitor (Ishikawa et al., 2002, Blood). Therefore, a Lyn specific inhibitor, either alone or in combination with other anti-MM drugs, may be a more effective regimen for the treatment of MM. INNO-406 is a novel inhibitor of ABL as well as Lyn. In laboratory-based studies, it has shown anti-tumor activity in hematological malignancies, especially in leukemia cells harboring BCR-ABL mutations (Kimura et al., 2005, Blood). Since Lyn is involved in MM cell proliferation, targeting Lyn may be an alternative therapeutic approach and improve the efficacy of other anti-MM agents. Thus, we conducted this study in order to determine the anti-MM effects of INNO-406. First, Western blot analyses demonstrated that Lyn was expressed in all MM cells analyzed, including bone marrow (BM) mononuclear cells derived from MM patients and MM cells from LAGκ1A, LAGκ1B and LAGκ2 xenografts, three of our unique in vivo SCID-hu models of human MM, which were originally developed from MM patient BM biopsies and have been maintained in SCID mice. However, Lyn activation, as demonstrated by phosphorylation of its downstream molecule HS1, was infrequently found in MM cells. INNO-406 inhibited the growth of the three MM cell lines tested including RPMI8226, U266 and MM1S. Interestingly, the U266 cell line is most resistant to INNO-406 among the three MM cell lines tested although its Lyn activation and expression level is the highest. Apoptosis analysis using flow cytometric analysis following Annexin V staining demonstrated that INNO-406 induced apoptosis in MM cells. When combined with melphalan, doxorubicin or bortezomib, INNO-406 synergistically inhibited MM cell growth. We are currently studying the molecular mechanisms of INNO-406's anti-MM effect, either alone or in combination treatment, and validating our in vitro findings using our unique in vivo mouse models of human MM. Updated data from these additional studies will be reported at the meeting. Disclosures: No relevant conflicts of interest to declare." @default.
• W2583508733 created "2017-02-10" @default.
• W2583508733 creator A5038431825 @default.
• W2583508733 creator A5040835019 @default.
• W2583508733 creator A5056678009 @default.
• W2583508733 creator A5058478767 @default.
• W2583508733 creator A5058820631 @default.
• W2583508733 creator A5061288330 @default.
• W2583508733 creator A5079971093 @default.
• W2583508733 creator A5085360438 @default.
• W2583508733 creator A5090300095 @default.
• W2583508733 date "2010-11-19" @default.
• W2583508733 modified "2023-10-12" @default.
• W2583508733 title "Synergistic Anti-Myeloma Effects of the Lyn Kinase Inhibitor INNO-406 In Combination with Doxorubicin, Melphalan and Bortezomib" @default.
• W2583508733 doi "https://doi.org/10.1182/blood.v116.21.5015.5015" @default.
• W2583508733 hasPublicationYear "2010" @default.
• W2583508733 type Work @default.
• W2583508733 sameAs 2583508733 @default.
• W2583508733 citedByCount "1" @default.
• W2583508733 countsByYear W25835087332020 @default.
• W2583508733 crossrefType "journal-article" @default.
• W2583508733 hasAuthorship W2583508733A5038431825 @default.
• W2583508733 hasAuthorship W2583508733A5040835019 @default.
• W2583508733 hasAuthorship W2583508733A5056678009 @default.
• W2583508733 hasAuthorship W2583508733A5058478767 @default.
• W2583508733 hasAuthorship W2583508733A5058820631 @default.
• W2583508733 hasAuthorship W2583508733A5061288330 @default.
• W2583508733 hasAuthorship W2583508733A5079971093 @default.
• W2583508733 hasAuthorship W2583508733A5085360438 @default.
• W2583508733 hasAuthorship W2583508733A5090300095 @default.
• W2583508733 hasConcept C108636557 @default.
• W2583508733 hasConcept C175818844 @default.
• W2583508733 hasConcept C184235292 @default.
• W2583508733 hasConcept C185592680 @default.
• W2583508733 hasConcept C190283241 @default.
• W2583508733 hasConcept C203014093 @default.
• W2583508733 hasConcept C2776364478 @default.
• W2583508733 hasConcept C2777478702 @default.
• W2583508733 hasConcept C502942594 @default.
• W2583508733 hasConcept C55493867 @default.
• W2583508733 hasConcept C57074206 @default.
• W2583508733 hasConcept C62112901 @default.
• W2583508733 hasConcept C71924100 @default.
• W2583508733 hasConcept C86803240 @default.
• W2583508733 hasConcept C95444343 @default.
• W2583508733 hasConceptScore W2583508733C108636557 @default.
• W2583508733 hasConceptScore W2583508733C175818844 @default.
• W2583508733 hasConceptScore W2583508733C184235292 @default.
• W2583508733 hasConceptScore W2583508733C185592680 @default.
• W2583508733 hasConceptScore W2583508733C190283241 @default.
• W2583508733 hasConceptScore W2583508733C203014093 @default.
• W2583508733 hasConceptScore W2583508733C2776364478 @default.
• W2583508733 hasConceptScore W2583508733C2777478702 @default.
• W2583508733 hasConceptScore W2583508733C502942594 @default.
• W2583508733 hasConceptScore W2583508733C55493867 @default.
• W2583508733 hasConceptScore W2583508733C57074206 @default.
• W2583508733 hasConceptScore W2583508733C62112901 @default.
• W2583508733 hasConceptScore W2583508733C71924100 @default.
• W2583508733 hasConceptScore W2583508733C86803240 @default.
• W2583508733 hasConceptScore W2583508733C95444343 @default.
• W2583508733 hasLocation W25835087331 @default.
• W2583508733 hasOpenAccess W2583508733 @default.
• W2583508733 hasPrimaryLocation W25835087331 @default.
• W2583508733 hasRelatedWork W1575204077 @default.
• W2583508733 hasRelatedWork W1986880818 @default.
• W2583508733 hasRelatedWork W2039670622 @default.
• W2583508733 hasRelatedWork W2107282910 @default.
• W2583508733 hasRelatedWork W2154842220 @default.
• W2583508733 hasRelatedWork W2538514347 @default.
• W2583508733 hasRelatedWork W2553838468 @default.
• W2583508733 hasRelatedWork W2558511132 @default.
• W2583508733 hasRelatedWork W2560139420 @default.
• W2583508733 hasRelatedWork W2562314043 @default.
• W2583508733 hasRelatedWork W2569243482 @default.
• W2583508733 hasRelatedWork W2571984329 @default.
• W2583508733 hasRelatedWork W2581181313 @default.
• W2583508733 hasRelatedWork W2588797611 @default.
• W2583508733 hasRelatedWork W2778283111 @default.
• W2583508733 hasRelatedWork W2943498492 @default.
• W2583508733 hasRelatedWork W2979490967 @default.
• W2583508733 hasRelatedWork W2979732157 @default.
• W2583508733 hasRelatedWork W2980195347 @default.
• W2583508733 hasRelatedWork W2988538273 @default.
• W2583508733 isParatext "false" @default.
• W2583508733 isRetracted "false" @default.
• W2583508733 magId "2583508733" @default.
• W2583508733 workType "article" @default.